Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-03-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
天康生物股份有限公司购买、出售资产的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the purchase and sale of assets by Tian Kang Biological Co., Ltd. It includes extensive information about the transaction overview, parties involved, shareholding percentages, financial data of the involved companies, approval procedures, transaction agreements, and risks. The content focuses on a specific asset acquisition transaction, including internal restructuring and share transfer details. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is not related to board changes, earnings releases, or legal proceedings. The document is a comprehensive disclosure about a capital transaction involving asset purchase and share acquisition, which fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual announcement of the transaction, not a mere notice or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-03-14 Chinese
吉林冠界生物技术股份有限公司资产评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report prepared by an independent asset appraisal company for Tian Kang Pharmaceutical (Suzhou) Co., Ltd. regarding its proposed acquisition of equity in Jilin Guan Jie Biotechnology Co., Ltd. The report includes valuation conclusions, detailed company and shareholder information, financial data, and the methodology used for valuation. It is a formal asset appraisal report, not a general financial report like an annual or interim report, nor is it an announcement or certification. The content and length (15,000 characters) indicate it is the full report itself. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone valuation report related to an acquisition, prepared according to regulatory standards and including audited financial data references, but it is not a full annual report or earnings release. 9M 2022
2023-03-14 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2023 Second Extraordinary General Meeting of Shareholders" of Tian Kang Biological Co., Ltd. It details the meeting date, voting methods, attendance, and the voting results on several proposals. It also includes a legal opinion from a law firm confirming the legality of the meeting and resolutions. There is no financial data or report content, only the official announcement of the voting results from the shareholders' meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2377 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2023-03-08 Chinese
关于天康生物股份有限公司2023年第二次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of Tian Kang Biological's 2023 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting process and voting results. It is not a report of financial results, audit, or management discussion, but a legal opinion related to a specific shareholders meeting. This type of document is typically associated with the Declaration of Voting Results & Voting Rights Announcements category, as it confirms the legality and results of shareholder votes at a general meeting. The document length is 3124 characters, which is relatively short and focused on legal opinion rather than full report content. Therefore, the best classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2023-03-08 Chinese
关于开展商品套期保值业务的可行性分析报告
Regulatory Filings Classification · 90% confidence The document is a detailed analysis report on the feasibility of conducting commodity futures hedging business by the company. It includes purpose, necessity, business scope, risk analysis, and risk control measures. It is not a financial report like an annual or interim report, nor is it an announcement of voting results or a regulatory filing. It is a specialized report related to risk management and business strategy concerning commodity futures hedging. This type of document does not fit into categories like earnings release, capital update, or management reports. Given the content and nature, it aligns best with a Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other specific categories, since it is a formal report submitted to the board and shareholders but not a financial statement or formal report type like 10-K or IR.
2023-02-20 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司可转换公司债券募投项目结项、终止并将剩余募集资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the completion, termination, and permanent supplementary use of remaining funds from a convertible bond fundraising project by 天康生物股份有限公司. It references regulatory guidelines related to fundraising and the management of raised funds, details the use and management of the funds, project completion status, termination reasons, and approval procedures including board and supervisory meetings. The document is not a full financial report but a regulatory compliance and verification report related to fundraising projects and their fund usage. It does not contain financial statements or earnings data but focuses on the regulatory and procedural aspects of fundraising project closure and fund reallocation. This fits the category of a Regulatory Filing (RNS) as it is a compliance and verification document related to fundraising and fund usage, not a full Annual Report, Interim Report, or Capital/Financing Update. The document length (7121 characters) and content confirm it is not a brief announcement but a substantive regulatory filing.
2023-02-20 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.